Deliver Your News to the World

GPC Biotech Announces Presentation of New Pre-Clinical Data on RGB-286638 Multi-Targeted Kinase Inhibitor at the American Society of Hematology Annual Meeting


Martinsried/Munich (Germany) and Princeton, N.J. – GPC Biotech AG (Frankfurt Stock Exchange: GPC, NASDAQ: GPCB) today reported that new pre-clinical data on RGB-286638, the Company’s multi-targeted protein kinase inhibitor, were presented at the 50th American Society of Hematology (ASH) Annual Meeting in San Francisco, California in a poster entitled, “RGB-286638, a Novel Multi-Targeted Small Molecule Inhibitor, Induces Multiple Myeloma (MM) Cell Death through Abrogation of CDK-Dependent and Independent Survival Mechanisms” (Poster Board II-853). The data presented demonstrate that, in a mouse tumor model, RGB-286638 inhibits the growth of multiple myeloma tumors and prolongs survival. Additionally, RGB-286638 has been shown to trigger apoptosis (programmed cell death) in multiple myeloma cells, including those cells that are resistant to drugs commonly used to treat this form of cancer. The data were presented by researchers at the Dana-Farber Cancer Institute and the Massachusetts General Hospital Cancer Center (MGH), Boston, Massachusetts.

“The data presented today suggest the potential role of RGB-286638 in the treatment of multiple myeloma,” said Martine George, M.D., Senior Vice President, Drug Development and Chief Medical Officer of GPC Biotech. “We are working with the MGH/Dana-Farber team to plan a Phase 1 study in hematological tumors, including multiple myeloma, which we expect to start in 2009. The first-in-humans study with this compound, a Phase 1 trial evaluating RGB-286638 in solid tumors, is expected to start in the near future.”

About RGB-286638
RGB-286638 is a multi-targeted protein kinase inhibitor entering Phase 1 clinical testing. The RGB-286638 compound has been shown in cancer cells to lead to the inhibition of cell cycle progression, the process that controls cell division and ensures the accurate duplication of genetic material, by targeting all relevant cyclin-dependent kinases, which are proteins involved in regulating the cell cycle. RGB-286638 has also been shown to induce apoptosis and to inhibit other major protein kinases that are important for the proliferation of cancer cells. In a range of pre-clinical models of solid and hematological tumors, RGB-286638 treatment results in tumor regression and increased survival.

GPC Biotech AG is a publicly traded biopharmaceutical company focused on anticancer drugs. GPC Biotech’s lead product candidate is satraplatin, an oral platinum compound. The Company has various anti-cancer programs in research and development that leverage its expertise in kinase inhibitors. GPC Biotech AG is headquartered in Martinsried/Munich (Germany) and has a wholly owned U.S. subsidiary in Princeton, New Jersey. For additional information, please visit GPC Biotech’s Web site at

This press release contains forward-looking statements, which express the current beliefs and expectations of the management of GPC Biotech. Such statements are based on current expectations and are subject to risks and uncertainties, many of which are beyond our control, that could cause future results, performance or achievements to differ significantly from the results, performance or achievements expressed or implied by such forward-looking statements. Actual results could differ materially depending on a number of factors, and we caution investors not to place undue reliance on the forward-looking statements contained in this press release. There can be no guarantee that RGB-286638 will be successfully developed. We direct you to GPC Biotech’s Annual Report on Form 20-F for the fiscal year ended December 31, 2007 and other reports filed with the U.S. Securities and Exchange Commission for additional details on the important factors that may affect the future results, performance and achievements of GPC Biotech. Forward-looking statements speak only as of the date on which they are made and GPC Biotech undertakes no obligation to update these forward-looking statements, even if new information becomes available in the future.


This news content was configured by WebWire editorial staff. Linking is permitted.

News Release Distribution and Press Release Distribution Services Provided by WebWire.